Role of anti-seizure drugs in stroke patients to prevent post stroke seizures
- Conditions
- Health Condition 1: null- Patients who had arterial or venous stroke
- Registration Number
- CTRI/2018/02/011926
- Lead Sponsor
- Department of Science and Technology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1. Patients with either ischemic stroke (arterial or venous occlusion) or parenchymal intracerebral haemorrhage (spontaneous non-aneurysmal, non-traumatic intracerebral haemorrhage) with a cortical syndrome (either parenchymal involvement documented by imaging (CT/MRI) or presence of seizures, aphasia, apraxia or agnosia)
2. Presenting within 1 week of onset in arterial stroke and within 2 weeks of confirmation of ICVT.
1. Previous history of epilepsy or treatment with an AED
2. Life expectation less than 1 month due to stroke or other life-threatening comorbidity
3. Subarachnoid or intraventricular hemorrhage
4. Isolated posterior circulation stroke involving brainstem or cerebellum
5. ICVT without cortical syndrome (clinical or radiological)
6. ICH due to brain tumor, trauma, vascular malformation, brain surgery or infection
7. Pre-existing dementia
8. Known allergy to Levieracetam
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Occurrence of a seizure.Timepoint: one year
- Secondary Outcome Measures
Name Time Method time from stroke to occurrence of a seizure, occurrence of early epileptic seizures after stroke, seizure severity, neurological function, midline shift, enlargement of hematoma, death (all cause), functional outcome assessed by Glasgow Outcome Scale and modified Rankin Scale and the occurrence of side effects of the trial medicationTimepoint: one year